Semaglutide vs tirzepatide: what to ask your provider

What each medication is

Semaglutide is a GLP-1 receptor agonist — it mimics the glucagon-like peptide-1 hormone, which influences appetite, satiety, and gastric emptying. It is FDA-approved under the brand names Wegovy (for chronic weight management) and Ozempic (for type 2 diabetes), with a once-weekly injection format.

Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates two related hormone pathways at once. It is FDA-approved under the brand names Zepbound (for chronic weight management) and Mounjaro (for type 2 diabetes), also a once-weekly injection.

What the trials show — and don't

Tirzepatide has shown larger average weight loss in head-to-head and indirect comparisons in clinical trials. Both medications have produced clinically meaningful results when prescribed appropriately and combined with lifestyle support.

Trial averages are not individual outcomes. Real-world response varies based on adherence, dose, comorbidities, and lifestyle context. A clinician interprets the trial evidence in the context of your specific situation.

Side-effect profiles overlap, but aren't identical

Both medications most commonly cause gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — especially during dose titration. Most patients find these manageable as the body adjusts.

Less common but more serious risks include pancreatitis, gallbladder disease, and others. Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. Your clinician walks through the specific risks for your health profile.

Questions worth asking

Which medication do you think fits my health profile, and why? Your clinician's reasoning is more useful than the headline trial number.

What does the dose-titration schedule look like, and how do we manage side effects during the early weeks?

How will we evaluate whether the medication is working — and how will we know if it isn't?

What's the plan for tapering or transitioning if we stop, and how long do you typically expect treatment to continue?

What does insurance coverage look like for each option given my plan?

Why your clinician picks, not a website

Choosing between semaglutide, tirzepatide, or neither is a medical decision that depends on factors only a clinician evaluating your full picture can weigh: comorbidities, current medications, contraindications, prior weight-loss history, and goals.

BridgeWell does not prescribe and does not steer patients toward a specific medication. The clinician at our independent clinical partner makes the prescribing decision based on what's best for you — or recommends a non-medication path if treatment isn't a fit.

Frequently asked